News

Under the deal, InMed’s Intelligent Cannabinoid Drug Design Platform (IDP) will be used to identify cannabinoid- and non-cannabinoid-based phytochemicals for ocular therapies focused on reducing various pro-inflammatory cytokines

The drug is approved in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA) in patients who achieve at least a partial response to prior

The open label single arm Phase II trial of PB272 monotherapy will involve a total of 70 patients with HER2-positive early stage breast cancer who have previously received

Temovate is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. The launch strengthens the company’s growing portfolio of valuable topical products and shows

As per the information, the OTC liquid drugs manufactured at the company’s Fort Washington facility, including Infants’ and Children’s Tylenol and Infants’ and Children’s Motrin, were adulterated. They

Laboratory analysis conducted by the FDA has confirmed that UltraZx contains sibutramine and phenolphthalein. Sibutramine is a controlled substance that was removed for safety reasons from the market

Both the organizations will jointly work on research projects to identify new drug candidates. The two parties said they have identified three initial projects with a focus on

TELESTAR will evaluate the safety and tolerability of telotristat etiprate and its effect on symptoms associated with carcinoid syndrome, while top-line data is expected to be reported in

Scleroderma causes fibrosis of skin, joints and internal organs and predominately affects women in mid-life. Resunab is a new, oral specialized pro-resolving mediator drug and it binds to